Table 3. Univariate and multivariate analyses for progression-free survival.
|
Univariate analysis
|
Multivariate analysis
|
|||
|---|---|---|---|---|
| Factor | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age, years | ||||
| <65 | 1 | 0.032 | 1 | 0.605 |
| ⩾65 | 0.69 (0.50–0.97) | 0.90 (0.61–1.33) | ||
| Gender | ||||
| Male | 1 | 0.387 | ||
| Female | 0.87 (0.62–1.20) | |||
| PS | ||||
| 0–1 | 1 | <0.001 | 1 | 0.026 |
| ⩾2 | 2.69 (1.64–4.21) | 2.04 (1.09–3.58) | ||
| Stage | ||||
| Locally advanced | 1 | 0.002 | 1 | 0.031 |
| Metastatic | 1.70 (1.21–2.40) | 1.47 (1.04–2.10) | ||
| CA19-9 | ||||
| Per 1000 increase | 1.01 (1.00–1.01) | 0.023 | 1.00 (0.99–1.01) | 0.559 |
| Group | ||||
| Non-HT | 1 | 1 | ||
| Non-ACEI/ARB with HT | 0.79 (0.49–1.22) | 0.294 | 0.97 (0.58–1.56) | 0.890 |
| ACEI/ARB | 0.51 (0.31–0.80) | 0.003 | 0.58 (0.34–0.95) | 0.032 |
Abbreviations: ACEI=angiotensin I-converting enzyme inhibitor; ARB=angiotensin II type-1 receptor blocker; CA19-9=carbohydrate antigen 19-9; CI=confidence interval; HR=hazard ratio; HT=hypertension; PS=performance status.